TFFP - TFF Pharmaceuticals inhaled niclosamide shows efficacy against Omicron

TFF Pharmaceuticals (TFFP +6.0%) said in vitro neutralization and viral replication assays suggested that its inhaled niclosamide product candidate completely inhibits viral replication of the Delta and Omicron variants of SARS-CoV-2. “Inhaled niclosamide’s demonstrable potency at such low concentrations should enable us to deliver reduced doses of the drug directly to the lung without compromising antirviral activity, thereby conferring a major potential advantage with respect to safety and tolerability,” said Glenn Mattes, CEO of TFF Pharmaceuticals. The company said that a phase 1 study has already demonstrated that a 6 mg BID dosing of inhaled niclosamide is well tolerated. The company said that it expects to complete phase 1 safety and pharmacokinetic data of inhaled niclosamide by end of 1Q’22.

For further details see:

TFF Pharmaceuticals inhaled niclosamide shows efficacy against Omicron